Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
August 31 2023 - 3:00PM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its senior management team will participate in
three upcoming investor conferences in September.
Conference Details:
Event: Citi 18th Annual BioPharma Conference
Details: Hosting investor meetings Thursday, September 7,
2023, in Boston, MA
Event: H.C. Wainwright 25th Annual Global Investment
Conference Details: Presenting in a fireside chat format on
Tuesday, September 12, 2023, at 8:30 AM ET and hosting investor
meetings in New York, NY
Event: Cantor Global Healthcare Conference
Details: Presenting in a fireside chat format on Thursday,
September 28, 2023, at 9:45 AM ET and hosting investor meetings in
New York, NY
To access webcasts of the H.C. Wainwright and Cantor
presentations, please visit the “Events & Presentations” page
within the Investors Relations section of Longboard’s website at
https://www.longboardpharma.com/. The presentations will be webcast
live and archived on the website for at least 30 days following the
events.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in
development for the potential treatment of seizures associated with
a broad range of Developmental and Epileptic Encephalopathies
(DEEs). LP352 is currently being evaluated in a Ph 1b/2a clinical
trial (the PACIFIC Study) in participants with DEEs, with data
expected around year-end 2023, as well as in additional supportive
studies. Longboard is also evaluating LP659, an oral, centrally
acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5
modulator, which is in development for the potential treatment of
multiple neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in the upcoming conferences and Longboard’s clinical
and preclinical programs and product candidates, ability to develop
product candidates and deliver medicines, and focus. For such
statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831463189/en/
CORPORATE CONTACT: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024